


Product data sheet



MedKoo Cat#: 555377 Name: GSK3039294 CAS: 1819986-22-5 Chemical Formula: C ₃₀ H ₄₄ N ₂ O ₁₄ Exact Mass: 656.2793 Molecular Weight: 656.682		
Product supplied as:	Powder	
Purity (by HPLC):	≥ 98%	
Shipping conditions	Ambient temperature	
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.	

1. Product description:

GSK3039294 is an orally available small molecule inhibitor of serum amyloid P component (SAP) binding to amyloid fibrils for the depletion of serum amyloid-P (SAP) component from the circulation.

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under “QC And Documents” section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	34.0	51.78

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.52 mL	7.61 mL	15.23 mL
5 mM	0.30 mL	1.52 mL	3.05 mL
10 mM	0.15 mL	0.76 mL	1.52 mL
50 mM	0.03 mL	0.15 mL	0.30 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of “Calculator”

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

1. Richards D, Bamford M, Liefwaard L, Haque N, Lewis G, Storey J, Fernando D, Kumar S, Thompson D, Holmes DS. Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro-drug of miridesap. Br J Pharmacol. 2020 Apr;177(8):1853-1864. doi: 10.1111/bph.14956. Epub 2020 Feb 11. PMID: 31877231; PMCID: PMC7070169.

In vivo study

1. Richards D, Bamford M, Liefwaard L, Haque N, Lewis G, Storey J, Fernando D, Kumar S, Thompson D, Holmes DS. Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro-drug of miridesap. Br J Pharmacol. 2020 Apr;177(8):1853-1864. doi: 10.1111/bph.14956. Epub 2020 Feb 11. PMID: 31877231; PMCID: PMC7070169.

7. Bioactivity

Biological target:

amyloid P-IN-1 is used in the research of diseases or disorders wherein depletion of serum amyloid P component (SAP), including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.

In vitro activity

Product data sheet



GSK294 was highly soluble and stable in simulated gastric and intestinal fluids, stable in intestinal microsomes, and permeable in Madine Darby Canine Kidney type II cells. GSK294 was rapidly hydrolysed to miridesap and its mono pro-drug ester in blood and liver microsomes.

Reference: Br J Pharmacol. 2020 Apr;177(8):1853-1864. <https://pubmed.ncbi.nlm.nih.gov/31877231/>

In vivo activity

GSK294 showed good oral bioavailability of miridesap in rats and dogs.

Reference: Br J Pharmacol. 2020 Apr;177(8):1853-1864. <https://pubmed.ncbi.nlm.nih.gov/31877231/>

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.